BridgeBio Oncology Therapeutics, Inc.
NASDAQBridgeBio Oncology Therapeutics heads into its May 13 earnings print with a striking gap between Wall Street's conviction and the market's recent drift. The analyst picture is unambiguously positive. Seven firms carry Buy or equivalent ratings on the stock, with a consensus price target near $25 — more than three times the current price of $8.13. Canaccord Genuity initiated with a…
Snapshot as of 24 Jun 2026
BridgeBio Oncology Therapeutics heads into its May 13 earnings print with a striking gap between Wall Street's conviction and the market's recent drift. The analyst picture is unambiguously positive. Seven firms carry…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BBOT — free to start on ORTEX.
Sign up for free →Open BBOT on ORTEX